Company / Financials
ANI Pharmaceuticals, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$883.4M
FY2025 · +43.8% YoY
Net Income
$78.3M
FY2025 · +522.9% YoY
Profit Margin
8.9%
FY2025 · net income / revenue
ROE
14.5%
FY2025 · return on equity
Total Assets
$1.4B
FY2025
Total Debt
$291.8M
0.54x debt/equity
Equity
$540.7M
FY2025
ROA
5.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$883.4M+43.8% YoYNet Income HistoryProfit after all expenses and taxes$78.3M+522.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$87.2MOperating Income HistoryProfit from core business operations before interest and taxes$111.1M+18922.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$317.7M+27.3% YoYR&D Expense HistoryResearch and development spending$51.7M+15.9% YoYInterest Expense HistoryCost of borrowing and debt obligations$32.6M-3.2% YoYIncome Tax HistoryTotal income tax expense$17.5M+573.0% YoYEPS (Basic) HistoryBasic earnings per share$0.86+128.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$0.85+127.9% YoY